Bristol-Myers Squibb (NYSE:BMY) Stock Holdings Raised by Guinness Asset Management LTD

Guinness Asset Management LTD lifted its stake in shares of Bristol-Myers Squibb (NYSE:BMYGet Rating) by 2.2% during the 1st quarter, HoldingsChannel.com reports. The firm owned 416,515 shares of the biopharmaceutical company’s stock after buying an additional 9,164 shares during the quarter. Bristol-Myers Squibb accounts for about 1.1% of Guinness Asset Management LTD’s holdings, making the stock its 27th biggest holding. Guinness Asset Management LTD’s holdings in Bristol-Myers Squibb were worth $30,418,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Steward Financial Group LLC bought a new position in shares of Bristol-Myers Squibb during the fourth quarter worth about $29,000. Horan Securities Inc. bought a new position in shares of Bristol-Myers Squibb during the fourth quarter worth about $29,000. Guardian Wealth Management Inc. bought a new position in shares of Bristol-Myers Squibb during the fourth quarter worth about $32,000. Consolidated Planning Corp bought a new position in shares of Bristol-Myers Squibb during the third quarter worth about $34,000. Finally, Leverty Financial Group LLC bought a new position in shares of Bristol-Myers Squibb during the fourth quarter worth about $37,000. 73.07% of the stock is currently owned by institutional investors and hedge funds.

BMY has been the topic of several research analyst reports. Raymond James cut shares of Bristol-Myers Squibb from an “outperform” rating to a “market perform” rating in a research report on Friday, June 3rd. They noted that the move was a valuation call. Wells Fargo & Company raised their target price on shares of Bristol-Myers Squibb from $65.00 to $70.00 and gave the stock an “equal weight” rating in a report on Tuesday, May 17th. Citigroup reissued a “buy” rating and issued a $90.00 target price on shares of Bristol-Myers Squibb in a report on Friday, June 3rd. Bank of America raised their target price on shares of Bristol-Myers Squibb from $78.00 to $80.00 and gave the stock a “buy” rating in a report on Monday, June 6th. Finally, BMO Capital Markets raised their target price on shares of Bristol-Myers Squibb from $87.00 to $92.00 in a report on Monday, May 2nd. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Bristol-Myers Squibb currently has an average rating of “Moderate Buy” and a consensus target price of $74.27.

In other Bristol-Myers Squibb news, EVP Sandra Leung sold 65,000 shares of the company’s stock in a transaction on Monday, June 6th. The stock was sold at an average price of $74.89, for a total value of $4,867,850.00. Following the transaction, the executive vice president now owns 308,627 shares of the company’s stock, valued at $23,113,076.03. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Giovanni Caforio sold 30,000 shares of the company’s stock in a transaction on Monday, June 13th. The shares were sold at an average price of $74.04, for a total value of $2,221,200.00. Following the completion of the transaction, the chief executive officer now directly owns 551,104 shares in the company, valued at approximately $40,803,740.16. The disclosure for this sale can be found here. Corporate insiders own 0.09% of the company’s stock.

BMY opened at $76.55 on Thursday. The business’s 50 day moving average is $75.93 and its 200-day moving average is $69.82. The stock has a market cap of $162.98 billion, a PE ratio of 27.15, a price-to-earnings-growth ratio of 1.62 and a beta of 0.49. The company has a current ratio of 1.32, a quick ratio of 1.23 and a debt-to-equity ratio of 1.18. Bristol-Myers Squibb has a twelve month low of $53.22 and a twelve month high of $78.61.

Bristol-Myers Squibb (NYSE:BMYGet Rating) last announced its earnings results on Friday, April 29th. The biopharmaceutical company reported $1.96 EPS for the quarter, topping the consensus estimate of $1.92 by $0.04. The firm had revenue of $11.65 billion for the quarter, compared to analysts’ expectations of $11.34 billion. Bristol-Myers Squibb had a return on equity of 48.37% and a net margin of 13.31%. The firm’s quarterly revenue was up 5.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.74 earnings per share. As a group, analysts forecast that Bristol-Myers Squibb will post 7.56 EPS for the current year.

The company also recently announced a quarterly dividend, which will be paid on Monday, August 1st. Shareholders of record on Friday, July 1st will be given a $0.54 dividend. The ex-dividend date of this dividend is Thursday, June 30th. This represents a $2.16 dividend on an annualized basis and a yield of 2.82%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is 76.60%.

Bristol-Myers Squibb Profile (Get Rating)

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis.

Featured Stories

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb (NYSE:BMYGet Rating).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.